Blueprint Medicines Corp · Q4 2022 earnings

Briefing

Blueprint Medicines reported fourth quarter and full year 2022 results.

Blueprint Medicines reported its Q4 and full year 2022 financial results, highlighting AYVAKIT's success as a standard of care for advanced systemic mastocytosis in the U.S. The company is nearing potential FDA approval of AYVAKIT for indolent SM and anticipates continued progress in clinical development programs.

• Achieved $204.0 million in total revenues in 2022, including $111.0 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues.
• Continued progress toward regulatory approvals of AYVAKIT/AYVAKYT for indolent systemic mastocytosis, with FDA granting priority review of a supplemental new drug application and EMA validating a type II variation marketing authorization application.
• Positive data from PIONEER trial of AYVAKIT in indolent systemic mastocytosis to be presented at the AAAAI Annual Meeting.
• The company anticipates approximately $130 million to $140 million in AYVAKIT net product revenues for advanced SM and GIST in 2023, and $40 million to $50 million in collaboration revenues from existing collaborations.

Headline financials

Revenue & EPS history

Blueprint Medicines anticipates approximately $130 million to $140 million in AYVAKIT net product revenues for advanced SM and GIST in 2023, and $40 million to $50 million in collaboration revenues from existing collaborations. This guidance excludes revenue from the anticipated AYVAKIT indication expansion in ISM in mid-2023.